Treatment

The Phase 3 STELLAR-303 trial tested zanzalintinib plus atezolizumab against regorafenib in patients with previously treated, non-MSI-high metastatic colorectal cancer. The study produced mixed results but achieved its main goal in the overall patient population. The combination did not significantly improve overall survival in patients without active liver metastases, although survival was longer than with […]

A growing body of evidence shows that starting treatment before surgery, known as a neoadjuvant-first approach, is helping more patients with locally advanced or borderline resectable pancreatic cancer become eligible for surgery and achieve longer survival. Experts emphasize that the best outcomes come from combining chemotherapy, radiation, surgery, and multidisciplinary care rather than relying on

Six-year follow-up data from the GARNET trial show that the immunotherapy drug Dostarlimab-gxly continues to provide durable benefits for patients with advanced or recurrent dMMR/MSI-H endometrial cancer who previously had limited treatment options after platinum-based chemotherapy. At a median follow-up of nearly 69 months, the overall response rate remained 45.5%, while complete responses increased from

Results from the Phase 2 NIVEC trial suggest that neoadjuvant nivolumab (Opdivo) may offer a highly effective treatment option for patients with stage I to III resectable mismatch repair–deficient (dMMR) endometrial cancer. Among 22 patients treated with nivolumab before surgery, 68.2% achieved a clinical complete response, with no evidence of cancer detected on imaging or

Teclistamab (Tecvayli) combined with daratumumab has emerged as a strong second-line treatment option for patients with relapsed or refractory multiple myeloma, especially for those who relapse after frontline quadruplet therapy and are not candidates for CAR T-cell therapy. In the phase 3 MajesTEC-3 trial involving 587 patients, the combination significantly outperformed standard therapy. Median progression-free

Trastuzumab pamirtecan (T-Pam; BNT323/DB-1303), a HER2-targeting antibody-drug conjugate, showed promising results in patients with advanced or recurrent HER2-expressing endometrial cancer who had progressed after chemotherapy and immunotherapy. In a phase 2 study of 145 patients with a median follow-up of 13.2 months, the treatment achieved a median progression-free survival of 8.0 months and a median

Results from the phase 3 PANKU-Breast02 trial showed that izalontamab brengitecan (iza-bren), a bispecific antibody-drug conjugate targeting EGFR and HER3, significantly improved outcomes in patients with previously treated advanced or metastatic triple-negative breast cancer (TNBC). Among 418 patients, iza-bren reduced the risk of disease progression or death by 71%, achieving a median progression-free survival of

An expert discussion highlighted how treatment of desmoid tumors has changed in recent years. Because many of these rare soft-tissue tumors can remain stable or even shrink on their own, doctors now often recommend active monitoring rather than immediate surgery, which has a high risk of recurrence. However, patients with growing or symptomatic tumors usually

A new analysis suggests that zanubrutinib may provide better outcomes than ibrutinib as a first-line treatment for patients with chronic lymphocytic leukemia (CLL). Researchers compared data from two separate Phase 3 clinical trials and adjusted for differences in patient characteristics to create a balanced comparison. The results showed that patients treated with zanubrutinib had a

Results from the Phase 2 ROSETTA Lung-02 study p suggest that pumitamig, an experimental bispecific antibody targeting PD-L1 and VEGF-A, may be a promising first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) when combined with chemotherapy. Among 40 patients enrolled in the study, the treatment achieved a 100% confirmed disease control rate.